Another Phase 2 trial of T‐DM1 in NSCLC with HER2 alterations (n = 7 for HER2 mutations) ended early owing to limited efficacy with an ORR of 6.7% and an mPFS of 2.0 months [22, 45]. Here, ERBB2 is linked to non-small cell lung carcinoma.